Navigation Links
New investigational compound targets pancreatic cancer cells
Date:9/15/2010

SCOTTSDALE, Ariz. (Sept. 14, 2010) A new investigational drug designed to penetrate and attack pancreatic cancer cells has been administered to a patient for the first time ever at the Virginia G. Piper Cancer Center at Scottsdale Healthcare.

ASG-5ME is a potent, targeted compound designed to selectively kill cancer cells, says Daniel Von Hoff, MD, a principal investigator in the Phase I clinical trial. Pancreatic cancer is a fast-growing and difficult to treat form of cancer, and is the fourth leading cause of cancer death in the United States.

"ASG-5ME is intended for pancreatic cancer patients who do not have a good prognosis with currently available therapies. We are very pleased to be able to offer this exciting agent in a clinical trial for patients with advanced pancreatic cancer," says Dr. Von Hoff. "Our goal at the Virginia G. Piper Cancer Center is to deliver cell-killing medicine through the best possible individually targeted therapies, and ASG-5ME fits the bill."

The new investigational compound uses a monoclonal antibody against a target which is found in more than 90 percent of pancreatic cancer patients. The monoclonal antibody delivers a highly potent molecule called monomethyl auristatin E (MMAE) to selectively kill the pancreatic cancer cells.

"It is a precision approach that is designed to avoid non-targeted cells, increasing antitumor activity in preclinical models and potentially reducing the toxic effects of traditional chemotherapy" says Dr. Von Hoff. Researchers are studying the drug to evaluate its safety and tolerability and identify the maximum tolerated dose.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare was the first to offer patient access to ASG-5ME. Researchers hope to enroll up to 50 patients in clinical trials of the drug in multiple centers across the U.S.

The drug was co-developed by Seattle Genetics, Inc. of Bothell, Wash. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc.

More than 36,000 people are expected to die from pancreatic cancer in 2010, according to the American Cancer Society. Most patients with advanced pancreatic cancer die within one year of diagnosis.

The Virginia G. Piper Cancer Center at Scottsdale Healthcare opened in 2001 as the first major cancer center in greater Phoenix to offer comprehensive cancer research, diagnosis, treatment, prevention and support services in a single location. The Commission on Cancer of the American College of Surgeons has awarded Accreditation with Commendation to the Scottsdale Healthcare cancer program.

Dr. Von Hoff is chief scientific officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and physician-in-chief at the Translational Genomics Research Institute (TGen).

Research at the Virginia G. Piper Cancer Center at Scottsdale Healthcare is conducted in collaboration with TGen and the Scottsdale Healthcare Research Institute, allowing molecular and genomic discoveries to reach the patient bedside as quickly as possible through clinical trials of therapies directed at specific targets in a patient's tumor.


'/>"/>

Contact: Keith Jones
kjones@shc.org
480-882-4412
Scottsdale Healthcare
Source:Eurekalert

Related medicine news :

1. Pivotal data for the investigational treatment PSD502 for primary premature ejaculation
2. Scott & White Healthcare researchers studying investigational agent that targets breast cancer
3. Compounds in non-stick cookware may be associated with elevated cholesterol in children and teens
4. Plant compound resveratrol shown to suppresses inflammation, free radicals in humans
5. Breast cancer cells regulate multiple genes in response to estrogen-like compounds
6. Concentration, timing and interactions are key when it comes to dietary compounds
7. Compound enhances cancer-killing properties of agent in trials
8. Researchers find compound effective in destroying antibiotic-resistant biofilms
9. New pyrimidine compounds may lead to improved treatments for childhood brain cancer
10. Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
11. Sigma-Aldrich Reaches Agreement to Sell Pfizers Bioactive Small Molecule Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... In the Health Care IT campaign, ... priority because it’s not if you will be attacked, but when.” However, he and ... to digital health care. , Improvements in auditing and monitoring have taken security in ...
(Date:2/24/2017)... ... ... Healthcare Associates of McKinney announced today that they have moved one ... 121, Suite 210, McKinney, Texas 75070. It is in the heart of the ... has grown, the need for more space has been paramount. This beautiful new ...
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have ... Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, ... Pro X. , With ProGlass Prism users are given the tools and effects ...
(Date:2/24/2017)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has published a ... an astounding statement when he says that the entire Bible was written for the ... times so plainly that anyone should be able to see the time period. He ...
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly ... Dyer started as the Chairman of the Management Committee when IFN was originally ... including the recruitment of investor/owners and development of the business plan. He became ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Following receiving CE Marking in Europe ... AMAR is a major milestone for the country where the device was developed ... market in Israel   ... inclusion in the National Health Basket , Israel , ... E-QURE Corp. (OTCQB: EQUR), a leader in medical devices for the treatment of advanced wound ...
(Date:2/24/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Empty Capsules Market is poised to grow at a ... billion by 2025. This industry report analyzes the market ... as regional levels presented in the research scope. The study provides historical ...
(Date:2/24/2017)... , Feb. 24, 2017 Physician General ... Drug and Alcohol Programs Jennifer Smith commended ... providing training for and using naloxone, a life-saving overdose ... McCullough , a recovery specialist and overdose survivor who ... EMS providers. "A significant part of fighting ...
Breaking Medicine Technology: